Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry
暂无分享,去创建一个
A. Poprach | B. Melichar | T. Buchler | O. Fiala | Julia Bohosova | M. Staník | R. Lakomy | R. Chloupková | I. Kiss | I. Penka | M. Zemanova | M. Holanek | K. Kopeckova | M. Holánek
[1] K. Bensalah,et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population. , 2019, Journal of Clinical Oncology.
[2] G. Zeng,et al. The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases , 2019, PloS one.
[3] M. Burotto,et al. Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma? , 2019, Journal of kidney cancer and VHL.
[4] R.C.E. van Velthoven,et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial , 2019, JAMA oncology.
[5] C. Porta,et al. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy , 2018, Targeted Oncology.
[6] K. Bensalah,et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[7] K. Ahrar,et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx). , 2018 .
[8] A. Matakidou,et al. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting , 2018, World Journal of Urology.
[9] J. Zapata-Copete,et al. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis , 2017, Investigative and clinical urology.
[10] S. Barni,et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[11] H. V. Van Poppel,et al. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. , 2016, European urology.
[12] Steven L. Chang,et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. Bensalah,et al. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. , 2015, Urologic oncology.
[14] T. Choueiri,et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.
[15] J. Brooks,et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era , 2014, International journal of cancer.
[16] E. Messing,et al. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. , 2014, Anticancer research.
[17] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[18] J. Haanen,et al. Do targeted agents offer clinical benefit as presurgical therapy? , 2014, World Journal of Urology.
[19] A. Poprach,et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database , 2012, Medical Oncology.
[20] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[21] B. Melichar,et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] S. Rosenberg,et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.
[23] B. Melichar,et al. Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis , 2009, Acta oncologica.
[24] C. Tangen,et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.
[25] N. Munshi,et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.
[26] R. Sylvester,et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.
[27] M Mazumdar,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Gore,et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. , 1994, British journal of urology.
[29] P. Choyke,et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. , 1993, The Journal of urology.
[30] T. Choueiri,et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. , 2011, The Journal of urology.
[31] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.